

## Quality improvement in colorectal cancer care; marching towards homegrown data.

P. Chandrasinghe

Department of Surgery, University of Kelaniya, Sri Lanka

**Keywords:** colorectal cancer, South Asia, Sri Lanka, quality improvement, data collection, survival.

### Background

Colorectal cancer (CRC) is currently the 3rd commonest cancer and the 2nd commonest cause of cancer deaths globally (1). Low and middle-income earning countries have experienced a recent surge in the incidence of CRC while there is a drop in incidence in the west (2)(3)(4). Sri Lanka has seen a steady increase in the incidence of CRC over the last two decades and it is currently the 3rd commonest cancer amongst Sri Lankans of both sexes (5). Currently 1.9 million new CRCs are diagnosed annually worldwide which is expected to increase up to 3.2 million new cases and 1.6 million deaths per year (6). The management of CRC has evolved significantly during the last century from a disease with almost 100% mortality in the early 20th century to a disease treated with curative intent for stage IV in the 21st century.

There is ample data on survival predictors and surgical quality parameters in colorectal cancer that were generated in the western populations (7–9). The human developmental index, genetics, social and environmental factors play a significant role in survival and the quality of surgical care (10–13). Therefore, direct application of available evidence on local populations is debatable. Hence there is a need for locally adopted data. Data on survival from CRC in Sri Lanka is scarce owing to the absence of a national programme for prospective data collection (14). Several authors have highlighted the lack of survival data and the possible inaccuracies of the existing incidence data in the Sri Lankan cancer registry (15). (14)

The North Colombo CRC database was established in the year 1995. Prospective data collection was done on all patients undergoing curative resections for CRC. The prospective data collection was initiated with printed pro-

forma and has currently developed to a point of care real time data entry into a cloud based data storage using the RedCap platform.

This oration presents the attempts of the North Colombo University Unit to develop locally applicable evidence in the improvement of patient care. Whilst each of the studies is presented and analysed separately, the discussion will focus on the value of data from Sri Lankan patients, including the ability to compare our results with international studies and will focus on the value of scientifically informed adoption of clinical treatment pathways for CRC in Sri Lankan patients.

### Methodology

Data is extracted from the North Colombo CRC database, from patients who underwent surgery with curative intent for CRC. Preoperative work up and management was standardized by protocol described in detail elsewhere (16). Neoadjuvant chemoradiotherapy (NCRT) was adopted for rectal cancers from the early 2000s and principles of enhanced recovery have been gradually incorporated to be a standard protocol. The same team at the university units performed surgery and histopathological assessment of the specimens. All postoperative complications were recorded and updated up to 30 days and at subsequent clinic visits. Anastomotic leakage was diagnosed with clinical evidence of intra-abdominal sepsis and ultrasound or CT evidence of intra peritoneal fluid.

Post operative surveillance is carried out with clinical examination coupled with carcino-embryonic antigen (CEA) levels three monthly for the first 2 years and biannually for 3 years. A colonoscopy and computer tomographic evaluation of the abdomen and pelvis at 1, 3 and 5 years post operative is undertaken.

Four areas pertaining to CRC management were assessed throughout this period. Namely, development of a locally feasible prognostic marker, response of the local population to NCRT, optimal nodal harvest in the local population with a survival advantage and improvement in patient outcomes over time.

Correspondence: P. Chandrasinghe

E-mail: prmodh@kln.ac.lk

 <https://orcid.org/0000-0002-3485-961X>

Received: 15-11-2023 Accepted: 29-11-2023

DOI: <http://doi.org/10.4038/sljs.v41i03.9099>



The ethics review committee at the University of Kelaniya medical school, Sri Lanka, approved the data base maintenance.

In selecting a cut-off value for serum preoperative albumin and optimum nodal harvest, serial increments were used instead of arbitrary values. Serially ascending values of 5 g/L of serum albumin were compared to define a finite cut-off value while serially ascending values of lymph nodes starting from a minimum of 5 were used. (17,18). Survival analysis was performed using Kaplan Meier curves while Kaplan-Meier analysis and Cox proportional hazard model were used for univariable analysis of confounding factors. For the significant confounders identified in the cohort for serum albumin, a type III analysis with a Weibull hazard model and

two-way interaction terms were used for multifactorial analysis while Cox-proportional hazard model was used for the group for optimum nodal harvest. Patients with both stage II and III with a minimum of 3 year follow up were included in the lymph node harvest analysis to minimise biases.


Only patients with mid and lower rectal cancer receiving NCRT were analysed to assess tumour response and its implications for survival (16). NCRT regime comprised radiotherapy (5040 cGy) to the true pelvis, which was delivered in 25 fractions combined with cyclical 5-fluorouracil. Patients underwent low or extended low anterior resection with TME of rectal cancer, abdomino perineal excision (APR), transanal resection of residual tumour at a median of 10 weeks (range 8–11 weeks) post NCR. Tumour regression grading (TRG) was done as described by Mandard et al. TRG 1 was a complete response with the absence of residual cancer and fibrosis extending through the wall; TRG 2 was the presence of residual tumour cells scattered through the fibrosis; TRG 3 was an increase in the number of residual cancer cells compared with TRG 1, in which fibrosis was predominant; TRG 4 was residual cancer outgrowing fibrosis and TRG 5 was the absence of regressive changes. Degree of TRG was grouped into subgroups; good regression – TRG 1 + 2; moderate regression – TRG 3; no regression – TRG 4 + 5, for the ease of analysis.

**Table 1.** Survival comparison using Kaplan-Meier method for serially ascending serum albumin levels. Reproduced from Chandrasinghe et al. 2013 (17)

Serum albumin level	5 year survival rates	P value
<20 g/L VS. ≥20 g/L	90% VS. 60%	0.44
<25 g/L VS. ≥25 g/L	90% VS. 59%	0.10
<30 g/L VS. ≥30 g/L	43% VS. 63%	0.04*
<35 g/L VS. ≥35 g/L	49% VS. 69%	0.02*
<40 g/L VS. ≥40 g/L	58% VS. 62%	0.48
<45 g/L VS. ≥45 g/L	58% VS. 73%	0.17

\* - significant value.

For survival assessment across time periods, Kaplan-Meier survival curves were used to compare survival pre and post 2010. The year 2010 was considered as a half-way point for the survival analysis as the authors believe it is an appropriate time point to mark the improvement in technical and adjunct treatment in the management of CRC. Also this enabled sufficient patient numbers for comparison in each group with



**Figure 1.** Kaplan-Meier survival curves for rectal cancer based on serum albumin level. . Reproduced from Chandrasinghe et al. 2013 (17)

**Table 2.** Percentage of each category of regression grade in rectal cancers receiving NCRT. Reproduced from Deen et al. 2023 (16)

Regression grade	Percentage
TRG 1	43.1% (Good)
TRG 2	12.7% (Good)
TRG 3	22.6% (Moderate)
TRG 4+5	21.6% (Poor)

Good vs. Moderate vs. Poor - Chi-Square=2.58; DF=2; P=0.28

an adequate follow-up period to evaluate long-term survival.

## Results

### *Preoperative albumin as a prognostic marker*


A total of 226 (male - 123 (54%) and female – 103) patients were studied (median age – 59 years; range 19-88, median follow up 36; range 10-160). 35 g/L was the cut-off serum albumin value at which most significant differences in survival emerged (Table 1). Forty-five patients (20%) of this cohort had hypoalbuminaemia (serum albumin < 3.5 g/L) according to this cutoff. Preoperative serum albumin of less than 35 g/L was associated with a significantly poor overall survivals following surgery for rectal cancer. (P=0.02; Figure 1).

Five-year overall survival rates between normo and hypoalbuminaemia groups were 69% versus 47%. The five-year disease free survival rate in the hypoalbuminaemia group was 69.7% compared to 83% in the normoalbuminaemia group (P = 0.02). Age, positive circumferential margin, perineural invasion, angio-invasion, lympho-vascular invasion, and advanced AJCC stage emerged as confounders in a univariable analysis while multi factorial model type III analysis of effects revealed that hypoalbuminaemia (P = 0.002), a positive circumferential margin (P = 0.002), and

AJCC stages III and IV compared with I and II (P = 0.003), were significant. Two-way interaction terms between the said factors using Weibull hazard model confirmed those factors to be independent risk factors for poor survival in rectal cancer.

Tumour response to neoadjuvant chemoradiotherapy and its effect on survival patterns in rectal cancer

Studying 153 patients with low or mid rectal cancer who received NCRT for locally advanced rectal carcinoma TRG 1 or TRG 2 was reported in 58.5% of the specimens. In total, 78.4% of patients showed tumour regression (TRG 1 - TRG 3) compared to 21.6% with either minimal or no tumour regression (TRG 4 + 5) (16). A median pathological tumour stage (T) of 2 was observed in good TRG, whereas poor TRG was associated with a median pathological T stage of 3 (Chi-square 16.6; DF = 2; P = 0.0002). Percentage response to NCRT was comparable between good (TRG 1 + 2), moderate (TRG 3) and poor (TRG 4 + 5) - (Chi-Square = 2.58; DF = 2; P = 0.28, Table 2). In all, 131 (79 male, 52 female; median age 57, interquartile range 47–62 years) patients who underwent low or ultra-low anterior resection of the rectum post-NCRT; 4 (3%) developed anastomotic leaks. Median follow-up at the time of analysis was 15 months (interquartile range 6–45 months).



**Figure 2.** Local recurrence free survival of rectal cancers based on tumour regression. Reproduced from Deen et al 2023 (16)

Local recurrence rate was 6.8% (9 of 131) and there was no significant difference in overall survival (Figure 2) or disease-free survival related to TRG. The 5-year disease-free survival rates for good, moderate and poor TRG did not differ significantly either (65%, 83% and 67% ; Chi-square – 0.01; DF – 2; P= 0.99).


**Optimum lymph node harvest from colorectal cancer specimens based on survival advantage**

Out of a total of 131 patients ( male – 56%, colon-55, rectal – 76, mean follow-up - 4.1 years; SD- 3.4), 61 had stage II and 70 had stage III cancer. The most significant survival benefit was seen with 14 or more nodes for both colon and rectal cancers (Table 3). For the total population of stages II and III CRCs, the maximum survival benefit was observed with 14 or more nodes (Figure 3). When stages II and III cancers were

separately analysed, a similar observation was made (stage II, p= 0.07; stage III, p=0.03).

Lower risk of death (Hazard ratio - 0.37, 95 % CI, 0.18–0.77; p=0.007) was observed when more than 14 lymph nodes harvested. Advanced age, male sex, LVI, and preoperative CEA levels were the other significant factors associated with survival in an initial multivariable analysis. The lymph node yield remained significant with a hazard ratio of 0.19 (95 % CI, 0.066–0.593; p=0.004) after adjusting for the above mentioned factors using multiple regression analysis with stepwise selection

A significantly lower lymph node yield was observed in those who had NCRT (NCRT- 8; range, 5–20 vs. no-NCRT- 11; range, 5–45; p=0.0128) (Table 4). Analysing the patients



**Figure 3.** Kaplan-Meier curves for colorectal cancers based on lymph nodes harvested. Reproduced from Chandrasinghe et al 2014 (18)

**Table 3.** Overall survival comparison in colon and rectal cancers based on ascending numbers of lymph nodes harvested from specimens. Reproduced from Chandrasinghe et al 2014 (18)

Lymph node groups	Rectal cancer; mean survival (SE) in years	p-value	Colon cancer; mean survival (SE) in years	p-value
<6 vs. ≥6	4.0 (1.38) and 3.4 (0.28)	0.759	1.9 (0.35) and 6.5 (0.44)	0.356
<7 vs. ≥7	3.7 (0.77) and 3.4 (0.30)	0.729	1.4 (0.53) and 6.6 (0.44)	0.125
<8 vs. ≥8	3.2 (0.56) and 3.6 (0.32)	0.445	1.6 (0.33) and 6.5 (0.48)	0.580
<9 vs. ≥9	3.6 (0.48) and 3.5 (0.35)	0.988	1.6 (0.22) and 6.6 (0.47)	0.505
<10 vs. ≥10	3.4 (0.44) and 3.6 (0.37)	0.628	2.2 (0.27) and 6.9 (0.46)	0.103
<11 vs. ≥11	3.3 (0.40) and 3.8 (0.39)	0.295	2.3 (0.22) and 6.8 (0.51)	0.426
<12 vs. ≥12	3.1 (0.36) and 4.3 (0.43)	0.050	3.8 (0.43) and 7.2 (0.42)	0.091
<13 vs. ≥13	3.2 (0.35) and 3.7 (0.36)	0.033	4.0 (0.35) and 7.0 (0.60)	0.093
<14 vs. ≥14	3.2 (0.34) and 3.7 (0.38)	0.032	3.9 (0.33) and 7.5 (0.59)	0.085
<15 vs. ≥15	3.4 (0.32) and 3.6 (0.46)	0.230	3.9 (0.33) and 7.5 (0.59)	0.085
<16 vs. ≥16	3.5 (0.31) and 3.6 (0.52)	0.340	4.0 (0.31) and 7.4 (0.67)	0.128
<17 vs. ≥17	3.5 (0.32) and 3.5 (0.52)	0.340	4.1 (0.29) and 7.3 (0.85)	0.331
<18 vs. ≥18	3.6 (0.77) and 3.3 (0.30)	0.344	4.2 (0.26) and 6.9 (1.30)	0.856

receiving NCRT in the same patient population, the median number of lymph nodes harvested in patients with a good and moderate regression (TRG 1 + 2 + 3) was 6 compared to a median of 8 in the poor regression (TRG 4 + 5) group (16).

#### Change in survival patterns in patients with CRC over time

In the pre – 2010 time period, there were 276 (65%) rectal cancer and 149 (35%) colon cancer (right colon – 68, left colon – 81) compared with 165 (57%) rectal cancers and 124 (43%) colon cancer s(right colon – 49, left colon – 76) in the post-2010 group.

Post-2010 period demonstrated a significantly better overall survival compared to pre-2010 ( $X^2= 12.1$ ;  $DF=1$ ;  $P<0.001$ ). There is also a significantly better disease free survival (DFS) ( $X^2= 19$ ;  $DF=1$ ;  $P<0.0001$ ) and overall survival (OS) ( $X^2= 19.1$ ;  $DF=1$ ;  $P<0.001$ ) in patients with rectal cancer in the post 2010 period compared to pre-2010. Both DFS ( $X^2= 1.8$ ;  $DF=1$ ;  $P=0.2$ ) and OS ( $X^2= 0.1$ ;  $DF=1$ ;  $P=0.8$ ) were comparable for colon cancers in the two time periods (Table 5).

#### Discussion

CRC. This was the first study to report preoperative serum albumin level as a marker of long-term outcome in rectal cancer (19) and has been later supported by evidence from other investigators (20–22). Toyiyama and colleagues have shown that stage II CRC with a low albumin level or a higher CRP fared worse and suggest that stage II CRC with a low GPI to be considered for adjuvant chemotherapy despite of the TNM stage (23). The importance of albumin in the local setting is that it is easily accessible at an affordable cost. More complex inflammatory markers of prognosis may be available with the limitation of cost and accessibility in a resource poor setting.

Although NCRT for rectal cancers has a clear benefit in DFS the response of the tumors to such treatment varies depending on many factors. Pathologists have developed various grading systems to classify the tumour response (24) and there is conflicting data on the variability of long-term

outcome for different regression grades (25–27). The pattern of TRG has not been published previously for a Sri Lankan population and is important as a country with limited access to radiation treatment (28). Also the study reveals our local recurrence rates for low and mid rectal cancers to be 6.8%, which is comparable to global benchmarks (29–31). In an era where complete responders can be offered organ preservation, further studies on tumour regression patterns is of high importance.

The indirect benefit of nodal assessment on survival may be observed due to accurate staging of the disease. Nodal harvest from CRC specimens is a team work between the surgeon and the pathologist. Sound surgical technique to include maximal mesentery in the specimen coupled with dissection techniques to increase nodal harvest (24,25). A previous study by Siriwardene et al on the same patient population has demonstrated pro-forma based reporting to enhance the reporting standards (26). Description of a cutoff value for local population is important in developing local management guidelines in the future for CRC. Furthermore, this analysis elaborates on the effect of NCRT for a reduced nodal harvest. This effect was previously demonstrated for the first time in a local population by Wijesuriya et al (27). It will be necessary to adopt cost effective techniques such as pre-operative tattooing to increase the nodal harvest in this patient group (28,29).

Understanding the survival pattern of the local population is pertinent for deciding the future direction of the particular surgical service. A long term outcome analysis of the local CRC population with prospectively collected data allows us to assess the quality of the care provided and compare with standards. The overall survival in CRC for this local population is 68%, which is comparable to that of the United States according to the National Cancer Institute data (30). Further the study provides evidence to the improvement in survival in rectal cancer patients probably owing to the continuous improvement preoperative imaging, neo-adjuvant treatment and perioperative care as opposed to colon cancer. This phenomenon has been observed in other populations as well (31). Hemminki and colleagues analyzing data of 5

**Table 4.** Effect of NCRT on median nodal harvest in CRC. Reproduced from Chandrasinghe et al 2014 (18)

	No NCRT	NCRT	
LN<14 (n)	73	18	Total=91
LN>14 (n)	38	02	Total=40
Median nodal harvest (range)	11 (5-45)	8 (5-20)	$p=0.0128$

NCRT neoadjuvant chemoradiation

**Table 5.** The overall survival from rectal and colon cancers in the pre and post 2010 time periods

Time	CRC population		Rectal cancer		Colon cancer	
	<2010	>2010	<2010	>2010	<2010	>2010
5-year OS	59%	68%	54%	69%	70%	69%

decades from a Finnish population suggest that the improvement in survival in rectal cancers can be attributed to a large number of small improvements and not a single breakthrough (31).

#### *Future challenges and the way forward*

Sri Lanka will also face few challenges in managing CRC in the near future. Several of these aspects have been looked into at North Colombo using our cohort. The global pandemic of young and early onset colorectal cancers (EOCRC) may have been an established phenomenon in the local setting. A 20% EOCRC and a 16% young cancer rate is observed in the North Colombo cohort (32,33). An aging population is another challenge that the developing is faced with. Due to this an increasing number of CRC in the elderly population is seen with unique challenges in management. The north Colombo cohort has demonstrated that the chronological age is not a predictor of poor outcome from surgery for CRC (34,35). Application of novel technologies is also challenging in this region due to the scarcity of resources and may need to be adapted to make them feasible in the local setting (35).

The most important perspective provided by these studies is the significance of maintaining prospective data. In a setting such as Sri Lanka where a centralized data collection and storage is lacking, the point of first contact is the best opportunity to capture individual patient data. While the national Cancer Control Programme maintained registries provides national data, the accuracy of the data collection sources is questionable. This is evident by the discrepancies in the CRC incidence by around 33% in the year 2017 provided by the same institute in the National Cancer registry and the Pathology based Cancer register (36,37). The North Colombo CRC database is now maintained as a cloud based electronic database. The infrastructure to manage online databases is present in Sri Lanka and several authors have demonstrated how prospective data could elaborate the landscape of patient care for better decision making (38,39). All units managing CRC should be encouraged to maintain updated data, which can be collaborated, in large multicenter studies to develop homegrown data. It is also an appropriate time to consider regional data hubs to collect data from the South Asian region which homes close to a 25% of the global population at present.

This is a synopsis of the SAARC oration 2023 delivered at the Sri Lanka Surgical congress 2023.

#### **References**

1. Fact Sheets by Cancer [Internet]. Available from: [http://globocan.iarc.fr/Pages/fact\\_sheets\\_cancer.aspx](http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx)

2. Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. *Gut*. 2017 Apr 1;66(4):683–91. DOI: 10.1136/gutjnl-2015-310912
3. Center MM, Jemal A, Smith RA, Ward E. Worldwide Variations in Colorectal Cancer. *CA Cancer J Clin*. 2009 Nov 1;59(6):366–78. DOI: 10.3322/caac.20038
4. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors. *Gastroenterology Review/Przegląd Gastroenterologiczny*. 2019;14(2):89–103. DOI: 10.5114/pg.2018.81072
5. National Cancer Control Programme [Internet]. [cited 2023 Jun 3]. Available from: <https://www.nccp.health.gov.lk/en>
6. Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. *Gut*. 2023 Feb 1;72(2):338–44. DOI: 10.1136/gutjnl-2022-327736
7. Pheby DFH, Levine DF, Pitcher RW, Shepherd NA. Lymph node harvests directly influence the staging of colorectal cancer: evidence from a regional audit. *J Clin Pathol*. 2004 Jan 1;57(1):43 LP–47. DOI: 10.1136/jcp.57.1.43
8. McDonald JR, Renehan AG, O'Dwyer ST, Haboubi NY. Lymph node harvest in colon and rectal cancer: Current considerations. *World J Gastrointest Surg*. 2012 Jan 27;4(1):9–19. DOI: 10.4240/wjgs.v4.i1.9
9. Höppener DJ, Stook JLPL, Galjart B, Nierop PMH, Nagtegaal ID, Vermeulen PB, et al. The relationship between primary colorectal cancer histology and the histopathological growth patterns of corresponding liver metastases. *BMC Cancer*. 2022;22(1):911. DOI: 10.1186/s12885-022-09994-3
10. Frederiksen BL, Osler M, Harling H, Jørgensen T. Social inequalities in stage at diagnosis of rectal but not in colonic cancer: a nationwide study. *Br J Cancer*. 2008;98:668–73. DOI: 10.1038/sj.bjc.6604215
11. Hultstrand C, Hörnsten C, Lilja M, Coe AB, Fjällström P, Hajdarevic S. The association between sociodemographic factors and time to diagnosis for colorectal cancer in northern Sweden. *Eur J Cancer Care (Engl)*. 2022;31. DOI: 10.1111/ecc.13687
12. Kelsall HL, Baglietto L, Muller DC, Haydon A, English DR, Giles GG. The effect of socioeconomic status on survival from colorectal cancer in the Melbourne Collaborative Cohort Study. *Soc Sci Med*. 2009;68 2:290–7. DOI: 10.1016/j.socscimed.2008.09.070
13. Coughlin SS. Social determinants of colorectal cancer risk, stage, and survival: a systematic review. *Int J Colorectal Dis*. 2020;35:985–95. DOI: 10.1007/s00384-020-03585-z
14. Wijeratne DT, Gunasekara S, Booth CM, Berry S, Jalink M, Carson LM, et al. Colorectal Cancer Treatment

- Characteristics and Concordance With Guidelines in Sri Lanka: Results From a Hospital-Based Cancer Registry. *JCO Glob Oncol*. 2022 May;8(8). DOI: 10.1200/GO.22.00004
15. Jayarajah U, Udayanga V, Fernando A, Samarasekera DN, Seneviratne S. The incidence and patterns of colorectal cancers in Sri Lanka from 2001 to 2010: Analysis of national cancer registry data. *Eur J Cancer Care (Engl)*. 2020 Jul 1;29(4):e13247. DOI: 10.1111/ecc.13247
16. Deen R, Ediriweera DS, Thillakaratne S, Hewavissanthi J, Kumarage SK, Chandrasinghe PC. Neoadjuvant Chemoradiation for Rectal Cancer Achieves Satisfactory Tumour Regression and Local Recurrence – Result of a Dedicated Multi-disciplinary Approach from a South Asian Centre. *BMC Cancer*. 2023 Dec 1. DOI: 10.1186/s12885-023-10769-7
17. Chandrasinghe PC, Ediriweera DS, Kumarage SK, Deen KI. Pre-operative hypoalbuminaemia predicts poor overall survival in rectal cancer: A retrospective cohort analysis. *BMC Clin Pathol*. 2013;13(1). DOI: 10.1186/1472-6890-13-12
18. Chandrasinghe PC, Ediriweera DS, Hewavissanthi J, Kumarage S, Deen KI. The total number of lymph nodes harvested is associated with better survival in stages II and III colorectal cancer. *Indian Journal of Gastroenterology*. 2014;33(3). DOI: 10.1007/s12664-013-0406-2
19. Nazha B, Moussaly E, Zaarour M, Weerasinghe C, Azab B. Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or inflammatory surrogate? *World J Gastrointest Surg [Internet]*. 2015 Dec 27;7(12):370–7. DOI: 10.4240/wjgs.v7.i12.370
20. Montomoli J, Erichsen R, Antonsen S, Nilsson T, Sørensen HT. Impact of preoperative serum albumin on 30-day mortality following surgery for colorectal cancer: a population-based cohort study. *BMJ Open Gastroenterol*. 2015 Dec 31;2(1):e000047. DOI: 10.1136/bmjgast-2015-000047
21. Shimura T, Toiyama Y, Hiro J, Imaoka H, Fujikawa H, Kobayashi M, et al. Monitoring perioperative serum albumin can identify anastomotic leakage in colorectal cancer patients with curative intent. *Asian J Surg*. 2018;41(1):30–8. DOI: 10.1016/j.asjsur.2016.07.009
22. Nazha B, Moussaly E, Zaarour M, Weerasinghe C, Azab B. Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or inflammatory surrogate? *World J Gastrointest Surg*. 2015 Dec 27;7(12):370–7. DOI: 10.4240/wjgs.v7.i12.370
23. Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, Kusunoki M. Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. *Exp Ther Med*. 2010/12/02. 2011 Jan;2(1):95–101. DOI: 10.3892/etm.2010.175
24. Tsai HL, Huang CW, Yeh YS, Ma CJ, Chen CW, Lu CY, et al. Factors affecting number of lymph nodes harvested and the impact of examining a minimum of 12 lymph nodes in stage I–III colorectal cancer patients: a retrospective single institution cohort study of 1167 consecutive patients. *BMC Surg*. 2016;16(1):17. DOI: 10.1186/s12893-016-0132-7
25. Sarli L, Bader G, Iusco D, Salvemini C, Mauro D Di, Mazzeo A, et al. Number of lymph nodes examined and prognosis of TNM stage II colorectal cancer. *Eur J Cancer*. 2005;41(2):272–9. DOI: 10.1016/j.ejca.2004.10.010
26. Siriwardana P, Pathmeswaran A, Hewavissanthi J, Deen K. Histopathology reporting in colorectal cancer: A proforma improves quality. *Colorectal Disease*. 2009 Oct 1;11:849–53. DOI: 10.1111/j.1463-1318.2008.01680.x
27. Wijesuriya RE, Deen KI, Hewavissanthi J, Balawardana J, Perera M. Neoadjuvant Therapy for Rectal Cancer Down-Stages the Tumor but Reduces Lymph Node Harvest Significantly. *Surg Today*. 2005;35(6):442–5. DOI: 10.1007/s00595-004-2956-5
28. Okada K, Sadahiro S, Ogimi T, Miyakita H, Saito G, Tanaka A, et al. Tattooing improves the detection of small lymph nodes and increases the number of retrieved lymph nodes in patients with rectal cancer who receive preoperative chemoradiotherapy: A randomized controlled clinical trial. *The American Journal of Surgery*. 2018;215(4):563–9. DOI: 10.1016/j.amjsurg.2017.06.030
29. Imaoka K, Yano T, Yoshimitsu M, Fukuhara S, Oshita K, Nakano K, et al. Preoperative endoscopic tattoo marking improves lymph node retrieval in laparoscopic rectal resection: a retrospective cohort study. *Ann Coloproctol*. 2021/09/16. 2023 Apr;39(2):115–22. DOI: 10.3393/ac.2021.00458.0065
30. Colorectal Cancer — Cancer Stat Facts [Internet]. [cited 2023 Jun 3]. Available from: <https://seer.cancer.gov/statfacts/html/colorect.html>
31. Hemminki K, Försti A, Hemminki A. Survival in colon and rectal cancers in Finland and Sweden through 50 years. *BMJ Open Gastroenterol*. 2021 Jul;8(1):e000644. DOI: 10.1136/bmjgast-2021-000644
32. Chandrasinghe P, Godahewa S, Mahendra G, Hewavissanthi J, Kumarage S. Trends in early onset colorectal cancer (EOCRC) in a South Asian cohort: data from a specialized tertiary care center in western Sri Lanka. *Sri Lanka Journal of Surgery*. 2022 Jul 31;40(2):24. DOI: 10.4038/sljs.v40i2.8978
33. Adamina M. Abstracts presented at the 14th European Colorectal Congress (#ECCStGallen), 29.11.2020–2.12.2020, St.Gallen, Switzerland. *Tech Coloproctol [Internet]*. [cited 2023 Sep 30];25. Available from: <https://doi.org/10.1007/s10151-021-02408-9>

34. Chandrasinghe PC, Ediriweera DS, Nazar T, Kumarage S, Hewavisenthi J, Deen KI. Overall Survival of Elderly Patients Having Surgery for Colorectal Cancer Is Comparable to Younger Patients: Results from a South Asian Population. *Gastroenterol Res Pract.* 2017;2017. DOI: 10.1155/2017/9670512
35. Chandrasinghe P, Kumarage S. Double single-port pan-proctocolectomy with transanal total mesorectal excision [TaTME] and ileal pouch-anal anastomosis [IPAA]: improvisation under limited resources. *Sri Lanka Journal of Surgery.* 2020; DOI: 10.4038/sljs.v38i3.8761
36. National Cancer Control Programme [Internet]. [cited 2023 Jun 3]. Available from: <https://www.nccp.health.gov.lk/en>
37. Mawatha E. Pathology-Based Cancer Frequency Data : Sri Lanka-2017 (Pathology Based Cancer Registry, Sri Lanka) National Cancer Control Programme Ministry of Health and Indigenous Medical Services 555/5.
38. Wijeyaratne M, Cassim R, Bradbury A, Hyrin A, Jayawickrema B, Weerasekera A, et al. Clinical Outcomes Following Lower Extremity Vein Bypass for Chronic Limb Threatening Ischaemia (CLTI) at the University of Colombo, Sri Lanka. *European Journal of Vascular and Endovascular Surgery.* 2020; 60(4): 560–6. DOI: 10.1016/j.ejvs.2020.06.039
39. Gamage B. Shifting the paradigm of peri-operative care in colorectal surgery in a Sri Lankan tertiary care unit. *Sri Lanka Journal of Surgery.* 2018 Dec 31;36(4):6. DOI: 10.4038/sljs.v36i4.8552